{"news_desk": "Science", "print_page": "10", "subsection_name": null, "section_name": "Health", "byline": {"contributor": "Abby Goodnough contributed reporting from Washington.", "original": "By KATIE THOMAS", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "1718", "keywords": [{"rank": "1", "value": "United States Politics and Government", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Insider Trading", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Ethics and Official Misconduct", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Collins, Christoper C", "is_major": "N", "name": "persons"}, {"rank": "6", "value": "Price, Thomas E (1954- )", "is_major": "N", "name": "persons"}, {"rank": "7", "value": "Innate Immunotherapeutics Ltd", "is_major": "N", "name": "organizations"}], "lead_paragraph": "Representatives Chris Collins and Tom Price and other power players have substantial investments in Innate Immunotherapeutics, a company with no approved drugs.", "pub_date": "2017-01-14T00:30:04+0000", "document_type": "article", "source": "The New York Times", "snippet": "Representatives Chris Collins and Tom Price and other power players have substantial investments in Innate Immunotherapeutics, a company with no approved drugs....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2017/01/14/science/14INNATE1/14INNATE1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2017/01/14/science/14INNATE1/14INNATE1-thumbWide.jpg"}, {"height": 405, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "405", "xlarge": "images/2017/01/14/science/14INNATE1/14INNATE1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2017/01/14/science/14INNATE1/14INNATE1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2017/01/14/science/14INNATE1/14INNATE1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2017/01/14/science/14INNATE1/14INNATE1-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2017/01/13/health/innate-immunotherapeutics-tom-price.html", "slideshow_credits": null, "blog": [], "_id": "5879795f95d0e0392607aacf", "headline": {"main": "Australian Drug Maker Has Low Profile but Powerful Backers in Washington", "print_headline": "Powerful Figures in Washington Invest in Tiny Australian Drug Maker"}}